Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis
Background Myosteatosis in cirrhotic patients has been evaluated in limited studies with conflicting results and no systematic review or meta-analysis have been performed in this setting. Methods We searched for all articles published until June 2023 to evaluate the prevalence of myosteatosis in cir...
Gespeichert in:
| Veröffentlicht in: | Hepatology international 2024-04, Vol.18 (2), p.688-699 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 699 |
|---|---|
| container_issue | 2 |
| container_start_page | 688 |
| container_title | Hepatology international |
| container_volume | 18 |
| creator | Kamiliou, Aikaterini Lekakis, Vasileios Chrysavgis, Lampros Cholongitas, Evangelos |
| description | Background
Myosteatosis in cirrhotic patients has been evaluated in limited studies with conflicting results and no systematic review or meta-analysis have been performed in this setting.
Methods
We searched for all articles published until June 2023 to evaluate the prevalence of myosteatosis in cirrhosis and chronic liver disease.
Results
Seventeen studies focused on cirrhosis and five studies in patients with chronic liver disease were included: the overall pooled prevalence of myosteatosis was 46% [95% Confidence Interval (CI) 36–57%] and 33% (95% CI 15–59%), respectively (
p
= 0.35). Among the studies with cirrhosis, the prevalence of myosteatosis was higher in those using the body mass index-based definition of myosteatosis (56%), than gender-based (36%) or other criteria (21%) (
p
0.05). Cirrhotic patients with myosteatosis, compared to those without myosteatosis, had more frequently a previous history of hepatic encephalopathy (32% vs 15%,
p
= 0.04), less frequently a previous history of variceal bleeding (46% vs 65%,
p
|
| doi_str_mv | 10.1007/s12072-023-10632-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11014812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2923909028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-4d8125dcdeba705dff248c5ce3aae289b25e7ba9a0516181697b4d9bb796c1583</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEoqXwBTggS1y4hPpPnNhcUFVBi1SJHsrZmjiTrqvEXmxnq_32eLtlgR44jaX383szelX1ltGPjNLuNDFOO15TLmpGW8Fr9aw6Zlq0NZUNe354C3FUvUrpjlIpW9a-rI6EElx3lB1Xm-uIG5jQWyTgB-LmNdhMgid5hSQs2Ya5zJHM25AyQg7JJeI8WUN26HMi9y6viHUxrnbSJwIkbQs5F92SYu7w_sF5xgw1eJi2BXtdvRhhSvjmcZ5UP75-uTm_rK--X3w7P7uqbdPJXDeDYlwOdsAeOiqHceSNstKiAECudM8ldj1ooJK1TLFWd30z6L7vdGuZVOKk-rz3XS_9jIMtG0eYzDq6GeLWBHDmX8W7lbkNG8MYZU0JLw4fHh1i-LlgymZ2yeI0gcewJMM1F5pqyndh75-gd2GJ5eJkBBWdEpIqXSi-p2wMKUUcD9swana9mn2vpvRqHno1O-t3f99x-PK7yAKIPZCK5G8x_sn-j-0veTWwqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3037835089</pqid></control><display><type>article</type><title>Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis</title><source>SpringerNature Journals</source><creator>Kamiliou, Aikaterini ; Lekakis, Vasileios ; Chrysavgis, Lampros ; Cholongitas, Evangelos</creator><creatorcontrib>Kamiliou, Aikaterini ; Lekakis, Vasileios ; Chrysavgis, Lampros ; Cholongitas, Evangelos</creatorcontrib><description>Background
Myosteatosis in cirrhotic patients has been evaluated in limited studies with conflicting results and no systematic review or meta-analysis have been performed in this setting.
Methods
We searched for all articles published until June 2023 to evaluate the prevalence of myosteatosis in cirrhosis and chronic liver disease.
Results
Seventeen studies focused on cirrhosis and five studies in patients with chronic liver disease were included: the overall pooled prevalence of myosteatosis was 46% [95% Confidence Interval (CI) 36–57%] and 33% (95% CI 15–59%), respectively (
p
= 0.35). Among the studies with cirrhosis, the prevalence of myosteatosis was higher in those using the body mass index-based definition of myosteatosis (56%), than gender-based (36%) or other criteria (21%) (
p
< 0.01); was higher in women than in men (61% vs 45%), in Child–Pugh class C than A or B (57% vs 49% vs 50%), in non-alcoholic fatty liver disease (NAFLD)- than viral-associated cirrhosis (57% vs 43%), but these differences were not statistically significant (
p
> 0.05). Cirrhotic patients with myosteatosis, compared to those without myosteatosis, had more frequently a previous history of hepatic encephalopathy (32% vs 15%,
p
= 0.04), less frequently a previous history of variceal bleeding (46% vs 65%,
p
< 0.01), were more likely to suffer from diabetes mellitus (27% vs 18%,
p
< 0.01), while they had higher mortality rates (40% vs 14%,
p
= 0.02).
Conclusion
Myosteatosis is highly prevalent in patients with cirrhosis, particularly in those with NAFLD-associated cirrhosis. Myosteatosis is associated with hepatic encephalopathy, while it seems to have a negative impact on the outcome.</description><identifier>ISSN: 1936-0533</identifier><identifier>ISSN: 1936-0541</identifier><identifier>EISSN: 1936-0541</identifier><identifier>DOI: 10.1007/s12072-023-10632-8</identifier><identifier>PMID: 38329701</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Body mass index ; Body size ; Cirrhosis ; Colorectal Surgery ; Diabetes mellitus ; Fatty liver ; Hepatic encephalopathy ; Hepatology ; Liver ; Liver cirrhosis ; Liver diseases ; Medicine ; Medicine & Public Health ; Meta-analysis ; Original ; Original Article ; Statistical analysis ; Surgery ; Systematic review</subject><ispartof>Hepatology international, 2024-04, Vol.18 (2), p.688-699</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-4d8125dcdeba705dff248c5ce3aae289b25e7ba9a0516181697b4d9bb796c1583</citedby><cites>FETCH-LOGICAL-c475t-4d8125dcdeba705dff248c5ce3aae289b25e7ba9a0516181697b4d9bb796c1583</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12072-023-10632-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12072-023-10632-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38329701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kamiliou, Aikaterini</creatorcontrib><creatorcontrib>Lekakis, Vasileios</creatorcontrib><creatorcontrib>Chrysavgis, Lampros</creatorcontrib><creatorcontrib>Cholongitas, Evangelos</creatorcontrib><title>Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis</title><title>Hepatology international</title><addtitle>Hepatol Int</addtitle><addtitle>Hepatol Int</addtitle><description>Background
Myosteatosis in cirrhotic patients has been evaluated in limited studies with conflicting results and no systematic review or meta-analysis have been performed in this setting.
Methods
We searched for all articles published until June 2023 to evaluate the prevalence of myosteatosis in cirrhosis and chronic liver disease.
Results
Seventeen studies focused on cirrhosis and five studies in patients with chronic liver disease were included: the overall pooled prevalence of myosteatosis was 46% [95% Confidence Interval (CI) 36–57%] and 33% (95% CI 15–59%), respectively (
p
= 0.35). Among the studies with cirrhosis, the prevalence of myosteatosis was higher in those using the body mass index-based definition of myosteatosis (56%), than gender-based (36%) or other criteria (21%) (
p
< 0.01); was higher in women than in men (61% vs 45%), in Child–Pugh class C than A or B (57% vs 49% vs 50%), in non-alcoholic fatty liver disease (NAFLD)- than viral-associated cirrhosis (57% vs 43%), but these differences were not statistically significant (
p
> 0.05). Cirrhotic patients with myosteatosis, compared to those without myosteatosis, had more frequently a previous history of hepatic encephalopathy (32% vs 15%,
p
= 0.04), less frequently a previous history of variceal bleeding (46% vs 65%,
p
< 0.01), were more likely to suffer from diabetes mellitus (27% vs 18%,
p
< 0.01), while they had higher mortality rates (40% vs 14%,
p
= 0.02).
Conclusion
Myosteatosis is highly prevalent in patients with cirrhosis, particularly in those with NAFLD-associated cirrhosis. Myosteatosis is associated with hepatic encephalopathy, while it seems to have a negative impact on the outcome.</description><subject>Body mass index</subject><subject>Body size</subject><subject>Cirrhosis</subject><subject>Colorectal Surgery</subject><subject>Diabetes mellitus</subject><subject>Fatty liver</subject><subject>Hepatic encephalopathy</subject><subject>Hepatology</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Original</subject><subject>Original Article</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Systematic review</subject><issn>1936-0533</issn><issn>1936-0541</issn><issn>1936-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kU9v1DAQxSMEoqXwBTggS1y4hPpPnNhcUFVBi1SJHsrZmjiTrqvEXmxnq_32eLtlgR44jaX383szelX1ltGPjNLuNDFOO15TLmpGW8Fr9aw6Zlq0NZUNe354C3FUvUrpjlIpW9a-rI6EElx3lB1Xm-uIG5jQWyTgB-LmNdhMgid5hSQs2Ya5zJHM25AyQg7JJeI8WUN26HMi9y6viHUxrnbSJwIkbQs5F92SYu7w_sF5xgw1eJi2BXtdvRhhSvjmcZ5UP75-uTm_rK--X3w7P7uqbdPJXDeDYlwOdsAeOiqHceSNstKiAECudM8ldj1ooJK1TLFWd30z6L7vdGuZVOKk-rz3XS_9jIMtG0eYzDq6GeLWBHDmX8W7lbkNG8MYZU0JLw4fHh1i-LlgymZ2yeI0gcewJMM1F5pqyndh75-gd2GJ5eJkBBWdEpIqXSi-p2wMKUUcD9swana9mn2vpvRqHno1O-t3f99x-PK7yAKIPZCK5G8x_sn-j-0veTWwqg</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Kamiliou, Aikaterini</creator><creator>Lekakis, Vasileios</creator><creator>Chrysavgis, Lampros</creator><creator>Cholongitas, Evangelos</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240401</creationdate><title>Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis</title><author>Kamiliou, Aikaterini ; Lekakis, Vasileios ; Chrysavgis, Lampros ; Cholongitas, Evangelos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-4d8125dcdeba705dff248c5ce3aae289b25e7ba9a0516181697b4d9bb796c1583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body mass index</topic><topic>Body size</topic><topic>Cirrhosis</topic><topic>Colorectal Surgery</topic><topic>Diabetes mellitus</topic><topic>Fatty liver</topic><topic>Hepatic encephalopathy</topic><topic>Hepatology</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Original</topic><topic>Original Article</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kamiliou, Aikaterini</creatorcontrib><creatorcontrib>Lekakis, Vasileios</creatorcontrib><creatorcontrib>Chrysavgis, Lampros</creatorcontrib><creatorcontrib>Cholongitas, Evangelos</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kamiliou, Aikaterini</au><au>Lekakis, Vasileios</au><au>Chrysavgis, Lampros</au><au>Cholongitas, Evangelos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis</atitle><jtitle>Hepatology international</jtitle><stitle>Hepatol Int</stitle><addtitle>Hepatol Int</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>18</volume><issue>2</issue><spage>688</spage><epage>699</epage><pages>688-699</pages><issn>1936-0533</issn><issn>1936-0541</issn><eissn>1936-0541</eissn><abstract>Background
Myosteatosis in cirrhotic patients has been evaluated in limited studies with conflicting results and no systematic review or meta-analysis have been performed in this setting.
Methods
We searched for all articles published until June 2023 to evaluate the prevalence of myosteatosis in cirrhosis and chronic liver disease.
Results
Seventeen studies focused on cirrhosis and five studies in patients with chronic liver disease were included: the overall pooled prevalence of myosteatosis was 46% [95% Confidence Interval (CI) 36–57%] and 33% (95% CI 15–59%), respectively (
p
= 0.35). Among the studies with cirrhosis, the prevalence of myosteatosis was higher in those using the body mass index-based definition of myosteatosis (56%), than gender-based (36%) or other criteria (21%) (
p
< 0.01); was higher in women than in men (61% vs 45%), in Child–Pugh class C than A or B (57% vs 49% vs 50%), in non-alcoholic fatty liver disease (NAFLD)- than viral-associated cirrhosis (57% vs 43%), but these differences were not statistically significant (
p
> 0.05). Cirrhotic patients with myosteatosis, compared to those without myosteatosis, had more frequently a previous history of hepatic encephalopathy (32% vs 15%,
p
= 0.04), less frequently a previous history of variceal bleeding (46% vs 65%,
p
< 0.01), were more likely to suffer from diabetes mellitus (27% vs 18%,
p
< 0.01), while they had higher mortality rates (40% vs 14%,
p
= 0.02).
Conclusion
Myosteatosis is highly prevalent in patients with cirrhosis, particularly in those with NAFLD-associated cirrhosis. Myosteatosis is associated with hepatic encephalopathy, while it seems to have a negative impact on the outcome.</abstract><cop>New Delhi</cop><pub>Springer India</pub><pmid>38329701</pmid><doi>10.1007/s12072-023-10632-8</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1936-0533 |
| ispartof | Hepatology international, 2024-04, Vol.18 (2), p.688-699 |
| issn | 1936-0533 1936-0541 1936-0541 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11014812 |
| source | SpringerNature Journals |
| subjects | Body mass index Body size Cirrhosis Colorectal Surgery Diabetes mellitus Fatty liver Hepatic encephalopathy Hepatology Liver Liver cirrhosis Liver diseases Medicine Medicine & Public Health Meta-analysis Original Original Article Statistical analysis Surgery Systematic review |
| title | Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A17%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20impact%20on%20the%20outcome%20of%20myosteatosis%20in%20patients%20with%20cirrhosis:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Hepatology%20international&rft.au=Kamiliou,%20Aikaterini&rft.date=2024-04-01&rft.volume=18&rft.issue=2&rft.spage=688&rft.epage=699&rft.pages=688-699&rft.issn=1936-0533&rft.eissn=1936-0541&rft_id=info:doi/10.1007/s12072-023-10632-8&rft_dat=%3Cproquest_pubme%3E2923909028%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3037835089&rft_id=info:pmid/38329701&rfr_iscdi=true |